JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jin, Z.-X.
Right arrow Articles by Yi, D.-H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jin, Z.-X.
Right arrow Articles by Yi, D.-H.
Related Collections
Right arrow Anesthesia
Right arrow Cardiac - physiology
Right arrow Extracorporeal circulation

J Thorac Cardiovasc Surg 2008;136:1450-1455
© 2008 The American Association for Thoracic Surgery


Cardiopulmonary Support and Physiology

The myocardial protective effects of a moderate-potassium adenosine–lidocaine cardioplegia in pediatric cardiac surgery

Zhen-Xiao Jin, MD, PhDa,*, Sheng-Li Zhang, MDa,*, Xi-Ming Wang, MDa, Sheng-Hui Bi, MDa, Mei Xin, MDa, Jing-Jun Zhou, PhDb, Qin Cui, MD, PhDa, Wei-Xun Duan, MD, PhDa, Hong-Bing Wang, MDa, Ding-Hua Yi, MD, PhDa,*

a Institute of Cardiovascular Surgery, Xijing Hospital, the Fourth Military Medical University, Xi'an, China
b Department of Physiology, the Fourth Military Medical University, Xi'an, China

Received for publication January 14, 2008; revisions received February 22, 2008; accepted for publication March 20, 2008.

* Address for reprints: Ding-Hua Yi, MD, PhD, Institute of Cardiovascular Surgery, Xijing Hospital, the Fourth Military Medical University, 17 Changle West Rd, Xi'an, China. (Email: yidinghua{at}yahoo.com.cn).


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 
Objectives: We sought to evaluate a moderate-potassium cardioplegic solution using adenosine and lidocaine as the arresting and protecting cardioprotective combination in pediatric cardiac surgery.

Methods: One hundred thirty-four patients with congenital heart disease were randomly allocated to one of 3 groups according to the cardioplegia formula used: the high-potassium (HP) group (K+, 20 mmol/L), 46 patients; the high-potassium adenosine–lidocaine (HPAL) group (K+, 20 mmol/L; adenosine, 0.7 mmol/L; and lidocaine, 0.7 mmol/L), 44 patients; and the moderate-potassium adenosine–lidocaine (MPAL) group (K+, 10 mmol/L; adenosine, 0.7 mmol/L; and lidocaine, 0.7 mmol/L), 44 patients. Hemodynamic data during the operation and postoperative data were recorded. Serum cardiac troponin I concentrations were examined at the time points of before cardiopulmonary bypass and 1, 3, 6, 12, and 24 hours after aortic crossclamp removal.

Results: At the end of cardiopulmonary bypass and modified ultrafiltration, the systolic and pulse pressures of the MPAL group were significantly increased compared with the respective values of the HP group. At the time points of 1 to 12 hours after reperfusion, the levels of serum cardiac troponin I were significantly decreased in the MPAL group compared with those in the HP and HPAL groups.

Conclusions: The MPAL cardioplegia formula was associated with better myocardial protective effects.



Abbreviations and Acronyms AL = adenosine–lidocaine; CPB = cardiopulmonary bypass; cTnI = cardiac troponin I; HP = high potassium; HPAL = high-potassium adenosine–lidocaine; ICU = intensive care unit; MPAL = moderate-potassium adenosine–lidocaine; MUF = modified ultrafiltration; PRBC = packed red blood cell



    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 
Currently, the majority of cardiac surgery centers use a high-potassium cardioplegic solution to arrest the heart during cardiac operations. The concentration of potassium is typically greater than 15 mmol/L.1Go Yet some studies have demonstrated that high-potassium cardioplegia can induce myocardial ionic and metabolic imbalances during ischemia and myocardial stunning, tissue edema, endothelial damage, free radical production, and functional loss during reperfusion.2Go

An alternative approach to arresting the heart is to maintain the transmembrane electrical potential in a polarized state,3Go which locks the ion channels in a "closed" state. Therefore ionic imbalances and subsequent consequences are likely to be avoided.3Go Adenosine triphosphate–sensitive potassium channel–opening agents (eg, nicorandil and aprikalim) have been used to achieve polarized or hyperpolarized arrest.2Go However, potassium channel–opening agents have been reported to increase postischemic arrhythmias and myocardial oxygen demand on reperfusion and to produce profound systemic hypotension. For these reasons, hyperpolarized arrest with a potassium channel–opening agent as the arresting agent has not been adopted as a clinical cardioplegic strategy.

The combination of adenosine and lidocaine is an alternative method to achieve polarized arrest.4Go In 2004, Corvera and colleagues4Go reported the effects of normokalemic adenosine–lidocaine (AL) cardioplegia on an isolated rat heart perfusion model. The AL cardioplegia was based on Krebs–Henseleit solution, which contained 0.2 mmol/L adenosine and 5 mmol/L lidocaine and in which the potassium concentration was 5.9 mmol/L. The theory underlying the experiment was that this normokalemic AL cardioplegia solution could arrest the heart and meanwhile maintain the myocardial cell membrane potential at the normal level (about –83 mV), which might avoid ion-channel activation and extra energy consumption and in turn might improve a protective effect. In 2005, Corvera and associates5Go reported their in vivo experimental study on a canine cardiopulmonary bypass (CPB) model, which demonstrated that the myocardial protective effects of warm or cold AL blood cardioplegia were equivalent to those of hypothermic potassium blood cardioplegia. The aim of this study was to investigate the cardioprotective effect of moderate-potassium AL cardioplegia in the clinical setting of pediatric cardiac surgery.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 
The study was performed according to the Declaration of Helsinki (revised version of Somerset West, Republic of South Africa, 1996) and all relevant Chinese laws. The study protocol was approved by the ethics committee of Xijing Hospital. All subjects provided written informed consent before inclusion in the study.

Composition of Cardioplegic Solutions
The basic cardioplegic solution was supplied by the clinical pharmacy of Xijing Hospital; 10% KCl solution, 2% lidocaine solution, and 0.3% adenosine solution were added before use by the perfusionist to achieve the various cardioplegic formulas. The compositions of the cardioplegic solutions are as follows:

high-potassium (HP) cardioplegia: Na+, 117 mmol/L; K+, 20.0 mmol/L; Mg++, 16 mmol/L; Ca++, 1.2 mmol/L; HCO3, 25 mmol/L, Cl, 140 mmol/L; glucose, 10 mmol/L; pH 7.48;
high-potassium AL (HPAL) cardioplegia: Na+, 117 mmol/L; K+, 20.0 mmol/L; Mg++, 16 mmol/L; Ca++, 1.2 mmol/L; HCO3, 25 mmol/L; Cl, 140 mmol/L; glucose, 10 mmol/L; lidocaine, 0.7 mmol/L; adenosine, 0.7 mmol/L; pH 7.48; and
• moderate-potassium AL (MPAL) cardioplegia: Na+, 117 mmol/L; K+, 10.0 mmol/L; Mg++, 16 mmol/L; Ca++, 1.2 mmol/L; HCO3, 25 mmol/L; Cl, 140 mmol/L; glucose, 10 mmol/L; lidocaine, 0.7 mmol/L; adenosine, 0.7 mmol/L; pH 7.48.

Experimental Design
We performed a prospective, single-center, randomized controlled study. After patients provided informed consent, they were randomly allocated either to the HP cardioplegia group, the HPAL cardioplegia group, or the MPAL cardioplegia group. The randomization was realized by messages sealed in envelopes passed to the perfusionist just before the operation, with the surgeons and intensive care physicians being unaware of the allocation.

Study Population
Patients given diagnoses of congenital heart disease for which a clinical decision was made to treat with a cardiac operation were eligible for enrollment. Patients who were cocommitted with other systemic diseases or reoperation or had undergone right or left ventricular incision were not included. One hundred thirty-four patients who were admitted in the institute of cardiovascular surgery, Xijing Hospital, between March 1, 2007, and May 31, 2007, were included in the present study. Go Table 1 summarizes the primary characteristics of the study population. There were no significant differences among the 3 groups with regard to age, sex, and body weight or defect types. The ratio of concomitant pulmonary hypertension among the 3 groups was also comparable, which indicated that the randomized allocation of the patients into 3 study groups was successful.


View this table:
[in this window]
[in a new window]

 
Table 1 Characteristics and congenital heart defect distributions among the 3 groups
 
Anesthesia, CPB, and Surgical Intervention
Anesthesia, CPB, and surgical intervention were performed by the same group of cardiac surgeons, perfusionists, and anesthetists. Anesthesia was induced and maintained with intravenous propofol (target-controlled infusion), sufentanil citrate, and atracurium. Patients' blood was heparinized before CPB with 300 IU/kg heparin, and the activated clotting time was maintained during CPB at a value greater than 480 seconds by using kaolin as the activating agent (ACT II HemoTec; Medtronic, Rueil Malmaison, France), with additional doses of heparin, as required. The CPB was set up with aortic cannulation and superior and inferior vena caval cannulation. The extracorporeal circuit was primed with various amounts of a balanced acetate solution containing 5% albumin, 0.5 g/kg mannitol, 2500 U of heparin, and 1 x 106 KIU aprotinin. Packed red blood cells (PRBCs) were added to the priming solution to maintain the CPB hematocrit value at approximately 0.25, and an appropriate volume of 5% NaHCO3 was added to correct the pH of the priming solution to 7.35 to 7.40. No calcium was added to the priming solution. A membrane oxygenator was used, and the appropriate flows were obtained with a roller pump (Stockert Instruments, Munich, Germany) during moderate hypothermia (esophageal temperature, 25°C–30°C) to maintain the venous oxygen saturation between 65% and 75%. If needed, conventional hemofiltration was used or extra PRBCs were added during the rewarming period of CPB to meet the oxygen consumption, and extra fluid was removed with modified hemofiltration to increase the hematocrit value to 0.32 to 0.35 after discontinuation of CPB. After discontinuation of CPB and modified hemofiltration, anticoagulation was reversed with protamine sulfate. Hypothermic myocardial protection was provided by aortic crossclamping and antegrade infusion of ice-cold cardioplegic solution, as described above, in a single dose of 20 mL/kg over 2 minutes. The cardioplegic solution was aspirated by means of vigorous suction at the coronary sinus to prevent its return into the CPB circuit.

Postoperative Management
Routine continuous postoperative monitoring included surface electrocardiography, transcutaneous pulse oximetry, and systemic arterial pressure measurement. Inotropic, chronotropic, and afterload-reducing agents were used as clinically indicated. Volume infusions (usually PRBCs or 5% albumin) were administered to maintain adequate filling pressures with systolic perfusion pressures. Diuretics (usually furosemide, 1-2 mg · kg–1 per dose) were begun on the first postoperative morning or earlier if the patient was oliguric (<1 cm3 · kg–1 · h–1).

Measurement of Serum Cardiac Troponin I Concentrations
For each patient, six 2-mL blood samples were taken: at the induction of anesthesia and again 1, 3, 6, 12, and 24 hours after arrival in the intensive care unit (ICU). The blood was transferred into dry glass tubes and stored at 4°C to 8°C for clot formation before centrifugation. Serum separated after centrifugation was frozen at –70°C until assay. The serum cardiac troponin I (cTnI) concentration was measured in the Department of Clinical Laboratory of our hospital in duplicate with an Access AccuTnI assay (Beckman Coulter, Fullerton, Calif) system by individuals unaware of the group allocation.

Data Collection
Preoperative and postoperative data were collected prospectively by the study team from the day of surgical intervention until hospital discharge. The preoperative data included age, sex, and body weight. The operative data include CPB time; aortic crossclamp time; total volume of cardioplegia; lowest temperature during CPB; hematocrit value before the operation, during CPB, and at the end of the operation; total volume of fluid output (ultrafiltration plus urine volume) during the operation; and hemodynamic parameters, including blood pressure data before the start of CPB, after the discontinuation of CPB, and at the end of modified ultrafiltration (MUF). The postoperative data included the number of hours of mechanical ventilation in the ICU, the number of days in the ICU, total volume of blood transfusion, total volume of chest drainage, and length of hospitalization after the operation. Any complications after the operation were also recorded. Serial data, such as serum cTnI concentration at different time points, were measured as described above. The inotrope scores6,7,8Go at different time points in the ICU were calculated as dopamine (x1) plus dobutamine (x1) plus amrinone (x1) plus milrinone (x15) plus epinephrine (x100) plus norepinephrine (x100) plus isoprenaline (x100).

Statistical Analyses
All continuous variables are expressed as means ± standard error of the mean, whereas discrete variables are presented as frequencies and percentages. Analyses of categorical variables were performed with the {chi}2 test. Analysis of continuous variables was performed with a 2-way analysis of variance, and multiple comparisons were made with post hoc least-significant-difference comparisons.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 
Overall Clinical Results and Safety Evaluation
All 3 cardioplegic solutions quickly arrested hearts within 2 minutes. There were no significant mechanical or electrical activities during the intracardiac operative period for all 3 groups. All the patients resumed spontaneous rhythm on aortic crossclamp removal, and there was no temporary pacing needed for any hearts. There were no deaths; no dialysis was necessitated because of renal failure, no cerebral impairment occurred, and no mediastinal reexploration was required because of postoperative bleeding in any of the 3 groups. There was a 6-month-old girl with ventricular septal defect and pulmonary hypertension in the MPAL group who underwent cardiopulmonary resuscitation and reintubation at the third postoperative day caused by vomiting and pulmonary aspiration. The resuscitation was successful, and the intubation was removed on the 15th postoperative day. She was discharged on the 24th postoperative day without any complications.

Comparison of Operative and Postoperative Parameters
As indicated in Go Table 2, the preoperative and operative parameters among the 3 groups were comparable with regard to aortic crossclamp time, CPB time, cardioplegia volume, lowest body temperature during CPB, hematocrit value (before the operation, during CPB, and at the end of operation), and fluid output during the operation.


View this table:
[in this window]
[in a new window]

 
Table 2 The operative and postoperative parameters of the 3 groups (mean ± SEM)
 
The total mediastinal drainage volume and the first mechanical ventilation time were comparable among the 3 groups; the reintubation time for the child in the MPAL group was not included in the statistical analysis. The ICU times of the 3 groups were comparable (P = .053). The postoperative hospital times of the 3 groups were comparable (P = .304).

Hemodynamic Changes During the Operation
Systolic and diastolic arterial pressures were recorded; pulse pressures were calculated according to the following equation: Pulse pressure=Systolic pressure–Diastolic pressure.

As indicated in Go Table 3, these 3 parameters changed in the same fashion, decreasing at the end of CPB and then increasing at the end of MUF. They were similar before the start of the CPB among the 3 groups. At the end of CPB, the systolic and pulse pressures of the MPAL group were significantly increased compared with the respective values of the HP group (68 ± 2.1 vs 62 ± 1.5 mm Hg [P = .013] and 29 ± 1.5 vs 25 ± 0.9 mm Hg [P = .029], respectively). At the end of MUF, the systolic and pulse pressures of the MPAL group were significantly increased compared with the respective values of the HP group (81 ± 1.7 vs 73 ± 1.6 mm Hg [P = .001] and 36 ± 0.9 vs 29 ± 1.1 mm Hg [P = .000], respectively). At the end of MUF, the systolic pressure of the HPAL group was increased compared with that of the HP group (78 ± 1.7 vs 73 ± 1.6 mm Hg [P = .030]), but the differences in pulse pressures between these 2 groups did not reach a statistically significant level (32 ± 1.1 vs 29 ± 1.1 mm Hg [P = .092]).


View this table:
[in this window]
[in a new window]

 
Table 3 Hemodynamic changes during surgical intervention in the 3 groups (mean ± SEM)
 
Serum cTnI Release
In the 3 groups the concentrations of serum cTnI before the operation were at similarly low levels. They surged to high levels after the removal of the aortic crossclamp, reached their highest level 3 hours after reperfusion, and then decreased in the same fashion but did not return to the preoperative baseline at 24 hours after removal of the aortic crossclamp (Go Table 4). However, at the time points from 1 to 12 hours after reperfusion, levels of serum cTnI were significantly decreased in the MPAL group compared with those in the HP and HPAL groups.


View this table:
[in this window]
[in a new window]

 
Table 4 Serial perioperative serum cTnI concentrations (mean ± SEM)
 
Inotrope Score
We evaluated inotropic drug use according to the inotrope scoring method previously used by our group, and there were no significant differences among the 3 groups. It seemed that the inotrope scores in the HP group were higher than those in the HPAL and MPAL groups at the time points of 1, 3, 6, 12, and 24 hours after ICU arrival, but analysis showed that the differences did not reach a statistically significant level (Go Table 5).


View this table:
[in this window]
[in a new window]

 
Table 5 Serial postoperative inotropic scale comparisons among the 3 groups (mean ± SEM)
 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 
Safety and Effectiveness
This clinical study compared the myocardial protective effects of different potassium concentrations during AL cardioplegia relative to classic high-potassium cardioplegia during hypothermia in pediatric patients with congenital heart defects. Because this was an explorative study, we enrolled patients with relatively simple heart defects that could be repaired without prolonged CPB time and heart arrest time. All 3 cardioplegic formulas arrested hearts quickly within 2 minutes. There were no significant mechanical or electrical activities during the intracardiac operative period in all 3 groups. There were no deaths, no dialyses necessitated by renal failure, no cerebral impairments, and no requirement for mediastinal reexploration caused by postoperative bleeding in the 3 groups. We conclude that the clinical use of HPAL and MPAL cardioplegia is safe and effective.

Correlation Between Cell Membrane Potential and Potassium Concentration in Cardioplegia
The cell membrane potential (VM in millivolts) can be calculated from the Nernstian distribution of K+ ions between the extracellular and intracellular phases as follows4Go:


Formula

where R is the universal gas constant (8.31 J %2219 mol–1 · K–1), F is Faraday's constant (96.49 KJ · mol–1 · V–1), T is absolute temperature (311.15 K), z is the valence of potassium ion (+1), and [K+]IN and [K+]OUT are the intracellular and extracellular concentrations of K+ ions in moles per liter, respectively. [K+]IN was estimated to be a constant value of about 88 to 89 mmol/L, and it was assumed that [K+]OUT was equal to the potassium concentration in the HP and HPAL cardioplegic formulas (20 mmol/L K+) and the MPAL cardioplegic formula (10 mmol/L K+). The cell membrane potential was approximately –46 mV when the HP and HPAL cardioplegic solutions were used and approximately –67 mV when the MPAL cardioplegic solution was used. Our results support the hypothesis that a less depolarized cell membrane during cardioplegic arrest is related to better myocardial protection and less reperfusion injury. This could be reflected by the better hemodynamic features during the operation and the decreased cTnI release during the early postreperfusion period in the MPAL group.

Mechanisms for MPAL Cardioplegia's Superiority Over HP Cardioplegia
The mechanisms for MPAL cardioplegia's superiority over HP cardioplegia were not investigated in the present study but have previously been extensively discussed by Dobson.6Go We summarize the main points as follows.

First, combined use of adenosine and lidocaine is related to better preservation of adenosine triphosphate, phosphocreatine, and glycogen stores and maintenance of a high cytosolic phosphorylation ratio during arrest, ischemia, and reperfusion.

Second, adenosine activates the A1 receptor subtype to exhibit its negative chronotropy, negative dromotropy, and negative inotropy, which contribute to arresting the heart. Furthermore, A1 receptor activation has been linked to the opening of the sarcolemmal adenosine triphosphate–sensitive K+ channel, stabilization of mitochondria mitochondrial permeability transition pore, and inhibition of the stimulatory effects of catecholamines.

Third, Lidocaine can block cardiomyocyte fast Na+ channels and effectively clamp the cell membrane near its resting membrane potential. Because fewer ion channels or pumps are activated at polarized potentials, the drug might reduce energy-sparing effects.

Fourth, because of fast Na+-channel blockade, the lidocaine and adenosine combination might further reduce Na+ and Ca++ loading.

Fifth, superior arrest and protection might also relate to the coronary vasodilatory properties of adenosine, lidocaine, and low potassium concentration, which result in reduced coronary vascular resistance and greater delivery of cardioplegia. This had been confirmed by the study of Dobson.4Go

Sixth, concentrations of potassium of greater than 15 mmol/L have been linked to left ventricular dysfunction and endothelial damage, and these deleterious effects are concentration dependent. Our results support these experimental studies and show that MPAL cardioplegia is linked with better hemodynamic features, including higher systolic pressures and pulse pressures at the end of CPB and MUF compared with the HP and HPAL groups.

Limitations of the Study
One of the limitations of this study was that the patients included in the study were all committed with simple congenital heart defects without cyanosis, and therefore the significance of the results might be very limited. Another limitation of this study was that we used systolic and pulse pressures to evaluate the hemodynamic performances of different groups. Because the pressure measurements were load dependent, this somewhat impaired their significance as perfect parameters of heart functions during the operation. Considering this was a controlled, blind, and randomized study, the pressure measurements still had some values to reflect the hemodynamic differences. The most important limitation of this study was that the cardioplegic formula we used was not a normokalemic one, which is somewhat different from Dobson's studies. A normokalemic cardioplegic solution might be better than the MPAL solution we used here, and the newest evidence from Dobson's laboratory9Go showed that normokalemic AL cardioplegia could be delivered intermittently or continuously with similar functional recoveries after a 40- or 60-minute arrest at 33°C in an isolated, perfused rat heart model. For safety reasons, we did not try the normal-potassium AL formula in a clinical setting. Corvera and associates5Go demonstrated that intermittent polarized arrest with warm or cold AL blood cardioplegia provided the same degree of myocardial protection as intermittent hypothermic K+–blood cardioplegia in a canine CPB model, but the AL solution did not show any superiority to traditional hyperkalemic cardioplegia. Whether normal-potassium AL cardioplegia is as safe and effective as MPAL cardioplegia in a clinical setting requires more experimental investigation.


    Conclusion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 
The combined use of adenosine and lidocaine in a moderate-potassium cardioplegic formula resulted in better myocardial protection.


    Acknowledgments
 
We thank Ying Yang for her excellent assistance in cardiomyocyte membrane potential calculation.


    Footnotes
 
Supported by the National 11th Five-year Science and Technology Supporting Project of China (2006BAI01A08) and Shaanxi Province Science and Technology Fund (2007K14-05[10]) and (2006K13-G1[2]).

* Drs Jin and Zhang contributed equally to this article. Back


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 

  1. Chambers DJ, Hearse DJ. Cardioplegia and surgical ischaemia. In: Sperelakis N, Kurachi Y, Terzic A, Cohen MV, editors. Heart physiology and pathophysiology. San Diego: Academic Press; 2001. pp. 887-926.
  2. Jayawant AM, Stephenson Jr. ER, Matte GS, et al. Potassium channel opener cardioplegia is superior to St. Thomas' solution in the intact animal. Ann Thorac Surg 1999;68:67-74.[Abstract/Free Full Text]
  3. Chambers DJ. Polarization and myocardial protection. Curr Opin Cardiol 1999;14:495-500.[Medline]
  4. Dobson GP, Jones MW. Adenosine and lidocaine: A new concept in nondepolarizing surgical myocardial arrest, Protection, and preservation. J Thorac Cardiovasc Surg 2004;127:794-805.[Abstract/Free Full Text]
  5. Corvera JS, Kin H, Dobson GP, et al. Polarized arrest with warm or cold adenosine/lidocaine blood cardioplegia is equivalent to hypothermic potassium blood cardioplegia. J Thorac Cardiovasc Surg 2005;129:599-606.[Abstract/Free Full Text]
  6. Shore S, Nelson DP, Pearl JM, et al. Usefulness of corticosteroid therapy in decreasing epinephrine requirements in critically ill infants with congenital heart disease. Am J Cardiol 2001;88:591-594.[Medline]
  7. Jin ZX, Zhou JJ, Xin M, et al. Postconditioning the human heart with adenosine in heart valve replacement surgery. Ann Thorac Surg 2007;83:2066-2072.[Abstract/Free Full Text]
  8. Wernovsky G, Wypij D, Jonas RA, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 1995;92:2226-2235.[Abstract/Free Full Text]
  9. Sloots KL, Vinten-Johansen J, Dobson GP. Warm nondepolarizing adenosine and lidocaine cardioplegia: continuous versus intermittent delivery. J Thorac Cardiovasc Surg 2007;133:1171-1178.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. M. Rudd and G. P. Dobson
Eight hours of cold static storage with adenosine and lidocaine (Adenocaine) heart preservation solutions: Toward therapeutic suspended animation
J. Thorac. Cardiovasc. Surg., December 1, 2011; 142(6): 1552 - 1561.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. Wu, P. Dong, C. Chen, J. Yang, and X. Hou
The Myocardial Protection of Polarizing Cardioplegia Combined With Delta-Opioid Receptor Agonist in Swine
Ann. Thorac. Surg., June 1, 2011; 91(6): 1914 - 1920.
[Abstract] [Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
Z. Jin, W. Duan, M. Chen, S. Yu, H. Zhang, G. Feng, L. Xiong, and D. Yi
The myocardial protective effects of adenosine pretreatment in children undergoing cardiac surgery: a randomized controlled clinical trial
Eur J Cardiothorac Surg, May 1, 2011; 39(5): e90 - e96.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
E.- H. Lee, H.- M. Lee, C.- H. Chung, J.- H. Chin, D.- K. Choi, H.- J. Chung, J.- Y. Sim, and I.- C. Choi
Impact of intravenous lidocaine on myocardial injury after off-pump coronary artery surgery
Br. J. Anaesth., April 1, 2011; 106(4): 487 - 493.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
G. P. Dobson
Membrane polarity: A target for myocardial protection and reduced inflammation in adult and pediatric cardiothoracic surgery
J. Thorac. Cardiovasc. Surg., December 1, 2010; 140(6): 1213 - 1217.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
K. L. Sloots and G. P. Dobson
Normokalemic adenosine-lidocaine cardioplegia: Importance of maintaining a polarized myocardium for optimal arrest and reanimation
J. Thorac. Cardiovasc. Surg., June 1, 2010; 139(6): 1576 - 1586.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jin, Z.-X.
Right arrow Articles by Yi, D.-H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jin, Z.-X.
Right arrow Articles by Yi, D.-H.
Related Collections
Right arrow Anesthesia
Right arrow Cardiac - physiology
Right arrow Extracorporeal circulation


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS